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Abstract
Background: Influenza A virus vaccines undergo yearly reformulations due to the antigenic variability of the virus caused by
antigenic drift and shift. It is critical to the vaccine manufacturing process to obtain influenza A seed virus that is
antigenically identical to circulating wild type (wt) virus and grows to high titers in embryonated chicken eggs. Inactivated
influenza A seasonal vaccines are generated by classical reassortment. The classical method takes advantage of the ability of
the influenza virus to reassort based on the segmented nature of its genome. In ovo co-inoculation of a high growth or yield
(hy) donor virus and a low yield wt virus with antibody selection against the donor surface antigens results in progeny
viruses that grow to high titers in ovo with wt origin hemagglutinin (HA) and neuraminidase (NA) glycoproteins. In this
report we determined the parental origin of the remaining six genes encoding the internal proteins that contribute to the
hy phenotype in ovo.
Methodology: The genetic analysis was conducted using reverse transcription-polymerase chain reaction (RT-PCR) and
restriction fragment length polymorphism (RFLP). The characterization was conducted to determine the parental origin of
the gene segments (hy donor virus or wt virus), gene segment ratios and constellations. Fold increase in growth of
reassortant viruses compared to respective parent wt viruses was determined by hemagglutination assay titers.
Significance: In this study fifty-seven influenza A vaccine candidate reassortants were analyzed for the presence or absence
of correlations between specific gene segment ratios, gene constellations and hy reassortant phenotype. We found two
gene ratios, 6:2 and 5:3, to be the most prevalent among the hy reassortants analyzed, although other gene ratios also
conferred hy in certain reassortants.
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Introduction
Due to the genetic instability of influenza viruses, caused by
antigenic drift and periodically antigenic shift, the influenza
vaccine needs to undergo yearly reformulations. To date the single
most practical method of preventing this acute respiratory disease
has been the inactivated influenza vaccine. Beginning in the 1940s,
the first inactivated vaccines were produced using field isolates,
termed wild type (wt) viruses. Wt virus was continuously passaged
in embryonated chicken eggs in order to obtain virus with the
growth properties needed for vaccine production [1–2]. A major
problem confronting vaccine production at that time was the low
viral titer obtained from wt virus growth in ovo.
The influenza A virus is a negative sense, single stranded RNA
virus. Its genome is composed of eight individual RNA segments
that encode eleven proteins. Segments 4 and 6 encode the two
surface glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), respectively. The remaining six gene segments encode
internal and non-structural viral proteins. The ribonucleoprotein
complex is composed of proteins encoded by: segment 1 (PB2),
segment 2 (PB1: this segment also encodes the pro-apoptotic
protein PB1-F2), segment 3 (PA) and segment 5 (NP). The shortest
gene segments, namely 7 and 8, are bicistronic. Segment 7 encodes
the matrix protein (M) and an ion channel protein (M2). Segment
8 encodes nonstructural protein 1 (NS1) and nuclear export
protein/nonstructural protein 2 (NEP/NS2) [3]. The segmented
structure of the genome allows for the exchange of the individual
gene segments between influenza viruses, a process defined as
reassortment.
In 1969, Edwin D. Kilbourne developed a method, now
referred to as the classical method, to prepare seed strains with an
in ovo high growth phenotype for preparation of influenza vaccines.
The classical method takes advantage of the segmented structure
of the influenza genome and its ability to reassort to produce high
yield (hy) reassortant influenza viruses for vaccine production [4].
A hy reassortant influenza vaccine virus must contain the HA and
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high titers in ovo. Hy reassortant vaccine viruses are generated by
co-inoculation of two viruses in ovo. The two viral parents being the
wt virus, which is the current circulating virus that causes disease
in a population in a particular year and the hy donor virus that is
well adapted for growth in embryonated chicken eggs resulting in
high viral titers. Concomitant infection allows for reassortment of
genetic segments between the two viruses. Antiserum is used for
negative selection against the hy donor surface glycoproteins and
in conjunction, adaptation to the host results in positive selection
for growth. The reassortant virus that is fittest outgrows other
viruses, thereby making this an evolutionary approach. The wt
virus provides the HA and NA gene segments, which encode the
surface antigens of the reassortant vaccine virus that elicit the
immune system to generate protective antibodies. The hy donor
virus provides the gene segments necessary to produce an in ovo
high growth phenotype [4–6]. The classical method revolutionized
the influenza vaccine manufacturing process.
An alternative approach to preparing seed virus for the
influenza vaccine is through reverse genetics. This process is
based on incorporating the six internal genes of the hy donor virus
and the two genes encoding the surface glycoproteins, HA and
NA, from the circulating wt virus into plasmids [7–11]. The
plasmids are subsequently transfected into cells to rescue the seed
virus. The seed virus generated by the reverse genetics method is
then inoculated into embryonated chicken eggs for vaccine
manufacturing. This system allows for the direct genetic
manipulation of the influenza gene segments. The avian influenza
virus (H5N1) vaccine has been prepared using reverse genetics
technology, as the HA gene segment of H5N1 needed to be
modified to reduce its virulence and permit growth of the virus in
embryonated chicken eggs for vaccine production [12–13].
A/Puerto Rico/8/1934 (PR8) is an H1N1 subtype that is highly
adapted to growth in embryonated chicken eggs. For the
inactivated influenza A vaccine both the classical method and
the reverse genetics technology implement PR8 or its gene
segments as their hy donor backbone. PR8 has been used as the hy
donor virus since the first hy reassortant virus, X-31b, was used in
a commercial influenza virus vaccine [4,14–15]. It has been
observed that reassortants that maintain the M gene segment
derived from PR8 have a hy phenotype [16–17]. Less is known
about the contribution of the remaining five internal genes to the
in ovo hy phenotype. Previous studies have shown that in addition
to the M gene, the other internal genes in different combinations
also contribute to the in ovo hy phenotype [16,18–20].
The present study analyzed the parental origin of each of the
eight gene segments for a panel of fifty-seven influenza A hy
reassortant viruses that were either vaccine candidates or used in
commercial vaccine production. Of the fifty-seven reassortants, 19
are H1N1 subtype and 38 are H3N2 subtype. The study also
includes the analysis of vaccine candidates and seed viruses used
for the 2009 H1N1pdm vaccine. The analysis was conducted using
reverse transcription-polymerase chain reaction (RT-PCR) and
restriction fragment length polymorphism (RFLP) [19,21–22].
Characterizing the gene segment ratios and gene constellations
that generate hy reassortants in embryonated chicken eggs should
assist in selecting the optimal reassortant seed strains needed for
vaccine production or in generating seed strains by reverse
genetics that will permit optimal growth.
The primary focus of this study was to evaluate the presence or
absence of correlations between specific gene segment ratios, gene
constellations and the hy reassortant phenotype in order to further
improve upon vaccine production strategies. Two gene ratios, i.e.
6:2 and 5:3 were the most prevalent found in the fifty-seven hy
reassortants analyzed. The wt PB1 gene segment was the most
frequent wt gene present in all gene ratios except 6:2. In contrast
the hy donor gene segment that was most prevalent was the M
gene segment, which was present in all gene ratios and found in
fifty-five out of fifty-seven hy reassortants analyzed.
Results
Subtype composition of hy reassortants and hy donor
viruses
In this study fifty-seven hy vaccine candidate reassortants
generated from thirty-one wt viruses were analyzed. To qualify as
a vaccine candidate reassortants must have a titer fold increase
greater than or equal to two compared to the respective wt parent.
Reassortants that did not fulfill this requirement were not
considered vaccine candidate viruses and were not analyzed in
this study. Therefore in this study the number of reassortants
analyzed from a single wt virus ranged from one to six.
Nineteen reassortants were derived from wt viruses that were
H1N1 subtype and thirty-eight were derived from wt viruses that
were H3N2 subtype (Table 1). Three hy donors were used to
generate the reassortants. PR8, subtype H1N1, HA titer 4096, was
used to generate the H3N2 reassortants. In contrast alternative hy
donors were used for the H1N1 reassortants, in order to have a
clear antigenic difference in the HA and NA subtype between the
hy donor and wt viruses, thereby allowing for optimal negative
selection. Two exceptions, X-53 and X-53a which are H1N1
reassortants were generated employing PR8 as the hy donor. Two
different hy donors, specifically X-31b and NYMC X-157, were
used for the generation of the H1N1 reassortants.
X-31b is an H3N2 hy reassortant resulting from a cross between
A/Aichi/2/1968 (H3N2 subtype) with PR8 [4]. It has a 6:2 gene
segment ratio, i.e. 6 genes from PR8 and 2 genes, HA and NA, from
A/Aichi/2/1968, and HA titer 4096. X-31b was the first reassortant
used in an experimental vaccine in 1971 [14]. Two reassortants
namely, X-127 (A/Beijing/262/1995) and X-139 (A/New Caledo-
nia/20/1999) were generated using X-31b as the hy donor (Table 1).
NYMC X-157 (H3N2 subtype) resulted from a cross between
A/New York/55/2004 (H3N2 subtype) with PR8. It has a 6:2
gene segment ratio and HA titer 2048. NYMC X-157 was used as
the H3N2 component in the 2005–2006 seasonal influenza
vaccine. Fifteen reassortants were generated using NYMC X-
157 as the hy donor. These include: NYMC X-163, X-163A, X-
163B (wt virus A/St. Petersburg/8/2006), NYMC X-173, X-
173A, X-173B, X-173C (wt virus A/South Dakota/06/2007),
NYMC X-177, X-177A, X-177B (wt virus A/Hong Kong/1870/
2008), NYMC X-179, X-179A (wt virus A/California/07/2009)
and NYMC X-181, X-181A, X-181B (wt virus A/California/07/
2009) (Table 1).
Viral genome restriction enzyme patterns
Analysis of restriction sites for the thirty-two wt viruses and hy
donor viruses was determined using available sequence data from
GenBank. Sequence data for each of the eight different viral gene
segments was analyzed. Sequences were not available for all the
H1N1 and H3N2 wt viruses; therefore a representative virus
sequence for each subtype was used for the analysis. The restriction
enzymes chosen for the analysis cut at one or two sites yielding two
and three fragments respectively. Differentiation between the hy
donor virus (PR8, X-31b or NYMC X-157) and the wt virus gene
segmentswas determined onthebasis ofdistinctbandsizes resultant
from restriction enzyme digestion of each gene segment.
A total of six different restriction enzymes were used in the
analysis of the eight gene segments (Table 2). One restriction
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Reassortants Wild Type Virus HA Titer* [FI]** Gene Constellation of HY Reassortants Gene Ratio
(hy reassortant
HA/wt HA) PB2 PB1 PA HA NP NA M NS
(hy donor:wt
virus)
H1N1 (hy donor PR8 was used for X-53, X-53a; hy donor X-31b was used for X-127, X-139; hy donor NYMC X-157 was used for the remaining H1N1 reassortants)
X-53 A/New Jersey/11/1976 512/16 [32] P WT P WT P WT P P 5:3
X53a
a A/New Jersey/11/1976 8192/16 [512] P WT P WT P WT P P 5:3
X-127
a A/Beijing/262/1995 1024/256 [4] P WT P WT P WT P P 5:3
X-139 A/New Caledonia/20/1999 512/128 [4] P WT P WT WT WT P P 4:4
NYMC X-163 A/St. Petersburg/8/2006 2048/32 [64] P P P WT P WT P P 6:2
NYMC X-163A A/St. Petersburg/8/2006 2048/32 [64] P P P WT P WT P P 6:2
NYMC X-163B A/St. Petersburg/8/2006 1024/32 [32] P P P WT P WT P P 6:2
NYMC X-173 A/South Dakota/06/2007 4096/128 [32] P P P WT P WT P P 6:2
NYMC X-173A A/South Dakota/06/2007 4096/128 [32] P P P WT P WT P P 6:2
NYMC X-173B A/South Dakota/06/2007 4096/128 [32] P P P WT P WT P P 6:2
NYMC X-173C A/South Dakota/06/2007 4096/128 [32] P P P WT P WT P P 6:2
NYMC X-177 A/Hong Kong/1870/2008 2048/256 [8] P P P WT P WT P P 6:2
NYMC X-177A A/Hong Kong/1870/2008 4096/256 [16] P P P WT P WT P P 6:2
NYMC X-177B A/Hong Kong/1870/2008 2048/256 [8] P P P WT P WT P P 6:2
NYMC X-179 A/California/07/2009 4096/64 [64] P WT P WT P WT P P 5:3
NYMC X-179A
b A/California/07/2009 2048/64 [32] P WT P WT P WT P P 5:3
NYMC X-181
b A/California/07/2009 4096/64 [64] P WT P WT P WT P P 5:3
NYMC X-181A A/California/07/2009 4096/64 [64] P WT P WT P WT P P 5:3
NYMC X-181B A/California/07/2009 2048/64 [32] P WT P WT P WT P P 5:3
H3N2 (hy donor PR8 virus was used in the reassortment of the H3N2 viruses)
X-117
a A/Beijing/32/1992 4096/512 [8] P P P WT P WT P P 6:2
X-121
a A/Shangdong/9/1993 512/128 [4] P P P WT P WT P P 6:2
X-123 A/Johannesburg/33/1994 2048/64 [32] P P P WT P WT P P 6:2
X-137 A/Moscow/10/1999 512/32 [16] P P P WT P WT P P 6:2
X-141 A/Panama/2007/1999 2048/64 [32] P P P WT P WT P P 6:2
X-143 A/Ulan Ude/01/2000 2048/256 [8] P P P WT P WT P P 6:2
X-145 A/California/32/1999 512/32 [16] P WT P WT P WT WT P 4:4
NYMC X-147
a A/Wyoming/03/2003 1024/16 [64] P P P WT P WT P P 6:2
NYMC X-149 A/Wyoming/03/2003 256/16 [16] WT WT WT WT P WT P P 3:5
NYMC X-151 A/Fujian/445/2003 2048/256 [8] WT PP WT WT WT P WT 3:5
NYMC X-153 A/Texas/40/2003 1024/64 [16] P P P WT WT WT P P 5:3
NYMC X-155 A/Wellington/01/2004 2048/64 [32] P P P WT P WT P P 6:2
NYMC X-157
a A/New York/55/2004 2048/64 [32] P P P WT P WT P P 6:2
NYMC X-157A A/New York/55/2004 2048/64 [32] P WT P WT P WT P P 5:3
NYMC X-157B A/New York/55/2004 1024/64 [16] P P P WT P WT P P 6:2
NYMC X-157C A/New York/55/2004 1024/64 [16] P P P WT P WT P P 6:2
NYMC X-157D A/New York/55/2004 2048/64 [32] P P P WT P WT P P 6:2
NYMC X-157E A/New York/55/2004 128/64 [2] WT WT WT WT P WT WT WT 1:7
NYMC X-159 A/Mississippi/05/2004 1024/64 [16] P P P WT P WT P WT 5:3
NYMC X-161
a A/Wisconsin/67/2005 512/64 [8] WT WT WT WT WT WT P WT 1:7
NYMC X-161B
a A/Wisconsin/67/2005 1024/64 [16] P P P WT P WT P P 6:2
NYMC X-165 A/Nepal/921/2006 2048/128 [16] P WT P WT P WT P P 5:3
NYMC X-167 A/Wisconsin/03/2007 256/16 [16] P WT P WT P WT P P 5:3
NYMC X-169 A/Brisbane/09/2006 2048/16 [128] P P P WT P WT P P 6:2
NYMC X-171 A/Brisbane/10/2007 1024/128 [8] WT WT WT WT WT WT P P 2:6
NYMC X-171A A/Brisbane/10/2007 256/128 [2] P WT P WT P WT P WT 4:4
NYMC X-171B A/Brisbane/10/2007 512/128 [4] P P P WT P WT P P 6:2
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and M. Two restriction enzymes were used in the analysis of gene
segments encoding PA, HA, NP, NA and NS. Five restriction
enzymes, namely PvuII, HindIII, XmnI, BsgI and SmlI, were used for
digestion of multiple gene segments. For example, PvuII was used to
digestPB2,PB1andHA,resultinginadistinct patternforeachgene
segment; HindIII was used to digest PA, HA and NP, also resulting
in a distinct pattern for each gene segment. PvuII showed consistent
digestion patterns, albeit at non-canonical cut sites, in the PB1 and
PB2gene segmentsofthe H3N2 subtypes;as wellasinthePB1gene
segment of PR8 (data not shown).A representative digestionpattern
of the eight gene segments of an H3N2 hy reassortant NYMC X-
197 (A/Brisbane/11/20106PR8) is shown in Figure 1 & 2.
Deviation from the predicted restriction sites within
subtypes
Within and among certain subtypes genetic variation, most
likely due to point mutations, resulted in different cleavage
patterns in contrast to the established cleavage patterns deter-
mined for the majority of the wt viruses in a respective subtype.
The novel cleavage pattern remained distinct enough to
differentiate between the hy donor and the wt virus. Therefore,
deviation from predicted restriction sites did not result in
ambiguities when determining the origin of a particular gene
segment. For example in the PB1 gene segment comparing A/
Fujian/445/2003 (NYMC X-151), H3N2 subtype, with other
digested H3N2 subtypes two distinct digestion patterns were
evident (data not shown). The M and NS gene segments, in
distinction to the remaining internal gene segments, showed no
variation from the predicted digestion patterns and were found to
be conserved among all the H1N1 and H3N2 viral subtypes.
Gene segment ratios and genetic constellations of hy
reassortants
Six distinct gene segment ratios were observed among the fifty-
seven hy reassortants analyzed (Table 1 & 3). Gene segment ratios
ranged from one gene segment originating from the hy donor and
the remaining seven gene segments originating from the wt virus
(1:7, hy donor: wt virus gene ratio), to six gene segments
originating from the hy donor and two gene segments originating
from the wt virus (6:2). The 1:7 gene segment ratio was present in
NYMC X-157E and NYMC X-161. The most prevalent gene
segment ratio, present in thirty-two reassortants, was six internal
gene segments derived from the hy donor and the two surface
glycoproteins (HA and NA) originating from the wt virus. The
second most prevalent gene segment ratio, present in seventeen
reassortants, was five gene segments from the hy donor and three
gene segments from the wt virus (5:3). This gene segment ratio in
addition to having the requisite two gene segments for HA and NA
originating from the wt virus also had one gene segment encoding
an internal protein (i.e. PB1, NP or NS). Three other gene segment
ratios were also present in the panel, three reassortants were 4:4,
two reassortants were 3:5 and one reassortant was 2:6.
Within the six different gene ratio groups twelve separate gene
constellations were observed among the fifty-seven hy reassortants
(Table 3). The observed distribution of gene constellations (12) was
statistically significant (p,0.00001) from the expected distribution
of 64. The reassortants with a 5:3 and a 4:4 gene segment ratio
had three distinct gene constellations; while the reassortants that
were 3:5 and 1:7 had two different gene constellations within their
respective gene ratio groups. Since the hy reassortants analyzed
were all vaccine candidates the HA and NA must be of wt origin,
therefore only one gene constellation was observed among the 6:2
reassortants. Only a single 2:6 hy reassortant was found and thus a
single gene constellation was determined.
Hemagglutination titers of hy reassortants in comparison
to respective wt virus
Hy reassortants by definition have enhanced growth in ovo,a s
measured by HA titers, when compared with their respective wt
virus. HA titers are not a direct measure of viral titers but provide
an indication of virus growth or yield. Hy reassortants were
defined as having a two fold or greater increase in HA titer
compared to the respective wt parent. In this analysis, among the
Reassortants Wild Type Virus HA Titer* [FI]** Gene Constellation of HY Reassortants Gene Ratio
(hy reassortant
HA/wt HA) PB2 PB1 PA HA NP NA M NS
(hy donor:wt
virus)
NYMC X-171C A/Brisbane/10/2007 1024/128 [8] P P P WT WT WT P P 5:3
NYMC X-171D A/Brisbane/10/2007 1024/128 [8] P P P WT WT WT P P 5:3
NYMC X-175A A/Uruguay/716/2007 512/128 [4] P WT P WT P WT P P 5:3
NYMC X-175C
a A/Uruguay/716/2007 2048/128 [16] P P P WT P WT P P 6:2
NYMC X-183 A/Wisconsin/15/2009 1024/16 [64] P P P WT P WT P P 6:2
NYMC X-185 A/Guangdong-Luohu/1256/2009 512/64 [8] P P P WT P WT P P 6:2
NYMC X-187
a A/Victoria/210/2009 1024/32 [32] P P P WT P WT P P 6:2
NYMC X-187A A/Victoria/210/2009 1024/32 [32] P P P WT P WT P P 6:2
NYMC X-189 A/Hong Kong/26560/2009 512/64 [8] P P P WT P WT P P 6:2
NYMC X-191 A/Philippines/219/2009 1024/128 [8] P P P WT P WT P P 6:2
NYMC X-197 A/Brisbane/11/2010 512/32 [16] P WT P WT P WT P P 5:3
*HA Titer is given as reciprocal of viral dilution at titration end point.
**[FI]: fold increase in HA titer over wt parent virus.
aUsed in seasonal influenza vaccine production.
bUsed in 2009 H1N1pdm vaccine production.
P: hy donor virus A/PR/8/1934 gene. WT: wild type virus gene.
doi:10.1371/journal.pone.0020823.t001
Table 1. Cont.
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titers were observed as compared to the wt virus (Table 1). Within
the panel of fifty-seven hy reassortants a two fold increase in HA
titer was recorded in two reassortants, NYMC X-157E (A/New
York/55/2004, 1:7) and NYMC X-171A (A/Brisbane/10/2007,
4:4). In contrast, X-53a (A/New Jersey/11/1976, 5:3) had a 512
fold increase in HA titer.
Fold increases in HA titer varied within reassortant groups that
had the same wt virus parent. In three reassortant groups, there
was a direct correlation between the greater number of gene
segments originating from the hy donor and the higher HA titer.
The reassortants generated for the wt virus A/Wisconsin/67/
2005, NYMC X-161 (1:7) and X-161B (6:2) had an 8 fold and 16
fold increase in HA titer, respectively. Likewise the two
reassortants NYMC X-147 (6:2) and X-149 (3:5) generated for
wt virus A/Wyoming/03/2003 had a 64 fold and 16 fold increase
in HA titer respectively. Similarly NYMC X-175A (5:3) and X-
175C (6:2) both generated from the wt virus A/Uruguay/716/
2007 showed an increase in HA titer of 4 fold and 16 fold,
respectively. In contrast the NYMC X-171 group had five
reassortants that were generated from A/Brisbane/10/2007: X-
171 (2:6), X-171A (4:4), X-171B (6:2), X-171C (5:3) and X-171D
Figure 1. Restriction Fragment Length Polymorphism Analysis of NYMC X-197 Polymerase and Nucleoprotein Gene Segments.
NYMC X-197 generated from A/Brisbane/11/2010 (H3N2)6A/PR/8/1934 (H1N1) has a 5:3 gene ratio, the PB1 gene segment was derived from wt virus;
PB2, PA and NP gene segments were derived from A/PR/8/1934. A. PB2: lane 1: A/PR/8/1934 undigested; 2: A/PR/8/1934 digested with PvuII; 3: A/
Brisbane/11/2010 undigested; 4: A/Brisbane/11/2010 digested with PvuII; 5: NYMC X-197 undigested; 6: NYMC X-197 digested with PvuII. B. PB1: lane
1: A/PR/8/1934 undigested; 2: A/PR/8/1934 digested with PvuII; 3: A/Brisbane/11/2010 undigested; 4: A/Brisbane/11/2010 digested with PvuII; 5:
NYMC X-197 undigested; 6: NYMC X-197 digested with PvuII. C. PA: lane 1: A/PR/8/1934 undigested; 2 and 3: A/PR/8/1934 digested with HindIII and
XmnI, respectively; 4: A/Brisbane/11/2010 undigested; 5 and 6: A/Brisbane/11/2010 digested with HindIII and XmnI, respectively; 7: NYMC X-197
undigested; 8 and 9: NYMC X-197 digested with HindIII and XmnI, respectively. D. NP: lane 1: A/PR/8/1934 undigested; 2 and 3: A/PR/8/1934 digested
with HindIII and XmnI, respectively; 4: A/Brisbane/11/2010 undigested; 5 and 6: A/Brisbane/11/2010 digested with HindIII and XmnI, respectively; 7:
NYMC X-197 undigested; 8 and 9: NYMC X-197 digested with HindIII and XmnI, respectively.
doi:10.1371/journal.pone.0020823.g001
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fold, with the highest fold increases found in the 5:3 and 2:6 gene
ratios.
Four reassortant groups had the same gene ratio and gene
constellation and differed in HA titers within the respective group.
Both X-53 and X-53a generated from A/New Jersey/11/1976
had a 5:3 gene ratio, but X-53 had a 32 fold increase while X-53a
had a 512 fold increase in HA titer. Three reassortants were
generated from wt virus A/St. Petersburg/8/2006, specifically
NYMC X-163 (6:2), X-163A (6:2) and X-163B (6:2). X-163 and
X-163A had a 64 fold increase in HA titer; in contrast X-163B
had a 32 fold increase in HA titer. Likewise, two of the three 6:2
reassortants generated from A/Hong Kong/1870/2008: NYMC
X-177 and X-177B had an 8 fold increase whereas, X-177A had a
16 fold increase in HA titer. Similarly three of the five hy
reassortants, all 5:3, developed from A/California/07/2009 for
the 2009 H1N1pdm vaccine, NYMC X-179, NYMC X-181 and
X-181A had a 64 fold increase in HA titer whereas NYMC X-
179A and X-181B had a 32 fold increase in HA titer. In contrast
two reassortant groups had the same gene ratio and gene
constellation and the same HA titer fold increase within the
respective group. Four H1N1 reassortants produced for A/South
Figure 2. Restriction Fragment Length Polymorphism Analysis of NYMC X-197 Glycoproteins, Matrix and Nonstructural Gene
Segments. NYMC X-197 derived the HA and NA gene segments from the wt virus and the M and NS gene segments from A/PR/8/1934. A. HA: lane
1: A/PR/8/1934 undigested; 2 and 3: A/PR/8/1934 digested with PvuII and HindIII, respectively; 4: A/Brisbane/11/2010 undigested; 5 and 6: A/Brisbane/
11/2010 digested with PvuII and HindIII, respectively; 7: NYMC X-197 undigested; 8 and 9: NYMC X-197 digested with PvuII and HindIII, respectively.
B. NA: lane 1: A/PR/8/1934 undigested; 2 and 3: A/PR/8/1934, digested with BsgI and Eco57I, respectively; 4: A/Brisbane/11/2010 undigested; 5 and 6:
A/Brisbane/11/2010 digested with BsgI and Eco57I, respectively; 7: NYMC X-197 undigested; 8 and 9: NYMC X-197 digested with BsgI and Eco57I,
respectively. C. M: lane 1: A/PR/8/1934 undigested; 2: A/PR/8/1934 digested with BsgI; 3: A/Brisbane/11/2010 undigested; 4: A/Brisbane/11/2010
digested with BsgI; 5: NYMC X-197 undigested; 6: NYMC X-197 digested with BsgI. D. NS: lane 1: A/PR/8/1934 undigested; 2 and 3: A/PR/8/1934
digested with SmlI and XmnI, respectively; 4: A/Brisbane/11/2010 undigested; 5 and 6: A/Brisbane/11/2010 digested with SmlI and XmnI, respectively;
7: NYMC X-197 undigested; 8 and 9: NYMC X-197 digested with SmlI and XmnI, respectively.
doi:10.1371/journal.pone.0020823.g002
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all had 6:2 gene ratios that resulted in a 32 fold increase in HA
titer. Likewise NYMC X-187 and X-187A, generated from A/
Victoria/210/2009, had 6:2 gene ratios and a 32 fold increase in
HA titer.
Discussion
Presently inactivated hy reassortants generated in embryonated
chicken eggs are used to produce 400 million yearly doses of
influenza vaccine [23]. Hy reassortants allow manufacturers to
produce the necessary amounts of virus for the seasonal vaccines in
a shorter time frame with smaller quantities of embryonated
chicken eggs. Although in seasonal epidemics we generally have
the infrastructure to provide influenza vaccination to the most at
risk groups as well as the general population; production
limitations were obvious when manufacturers were confronted
with the need to produce the 2009–2010 seasonal vaccine as well
as the 2009 H1N1 pandemic vaccine. The current composition of
the influenza vaccine is trivalent, with two influenza A
components, H1N1 and H3N2, and one influenza B component
(Victoria or Yamagata lineage) [24].
A crucial aspect to the vaccine manufacturing process is to
obtain influenza A seed virus that has the ability to grow well in
embryonated chicken eggs. Currently there are two methods for
generating hy influenza A seed strains for vaccine manufacturing,
the classical method and reverse genetics. The classical method,
which does not use a fixed gene ratio, strictly uses embryonated
chicken eggs throughout the process. To date, this is the current
method used for the generation of all of the seasonal inactivated
influenza A vaccine prepared in ovo. Reverse genetics in contrast
employs a fixed 6:2 gene ratio and must rescue its influenza seed
virus from cell culture before it can be propagated in embryonated
chicken eggs. When growth was evaluated in a direct comparison
with the hy reassortants made using the classical method, the
reverse genetics reassortants frequently did not show enhanced
growth [25]. Although reverse genetics is a powerful tool for the
direct manipulation of the gene segments, the classical method has
three advantages. First this method allows for natural reassortment
of two viruses to take place within the host, thus the reassortant
seed virus is highly adapted to the egg host from the earliest stage.
Secondly this method does not employ a fixed gene ratio and
allows for the selection of the gene ratio and gene constellation that
will result in the highest growth phenotype. Lastly the wt target
virus and the hy donor A/PR/8/1934 virus are not cloned;
therefore variants of all genes including the hemagglutinin and
neuraminidase are selected within the egg host to produce the
reassortant with the highest growth.
Hy reassortants are the progeny of two distinct influenza viral
subtypes. The genome of each parent virus is comprised of eight
gene segments and therefore the possible combinations that could
result in their progeny are 2
8 or 256 combinations. However in
order to immunize a susceptible population, the two surface
glycoproteins must derive their gene segments from the wt virus.
Therefore six genes remain available for reassortment, resulting in
2
6 or 64 possible combinations. In addition to the gene segment
combinations resulting from reassortment, pre-existing variants
and virus mutations selected during adaptation to the egg host also
occur. The importance of these variants in selection for adaptation
for high yield is well illustrated by X-53 and X-53a (A/New
Jersey/11/19766PR8), both were 5:3 reassortants prepared for
the swine flu vaccine in 1976. X-53 and X-53a were not
antigenically distinguishable, but a single amino acid change in
the HA gene increased the yield of X-53a by 16-fold in
comparison to X-53 [26–28]. With 64 different possible
combinations due to reassortment, in addition to variants
generated by point mutations, it is important to improve our
understanding of which gene segment ratios and gene constella-
tions produce the most efficient hy reassortants.
Baez et al. (1980) stated that the genes from the hy donor virus
may function in an additive manner and therefore the highest
yielding reassortants should contain the majority of the internal
genes from the hy donor virus. Generally this held true in our
analysis, but there were exceptions. The additive phenomena can
be clearly seen in the NYMC X-161 reassortant family, in the
NYMC X-175 reassortant family and in the two reassortants
NYMC X-147 and X-149. In all three of these reassortant families
the greater number of gene segments originating from the hy
donor the greater the fold increase in HA titer found for the
reassortant. In contrast the NYMC X-171s were an exception to
this pattern. Of the five reassortants in this family a greater fold
increase was seen in the reassortants that had 5:3 and 2:6 gene
ratios; in contrast, a lower fold increase was seen in the reassortant
with a 6:2 gene ratio.
Certain hy reassortants generated from the same wt virus and
with the same 6:2 gene ratio differed in their fold increase in HA
Table 2. Restriction Enzymes used for RFLP.










Gene segments PB2, PB1 and M were digested by a single enzyme.
*SmlI was used to digest 2009 H1N1pdm M gene segment.
doi:10.1371/journal.pone.0020823.t002
Table 3. Gene Constellations Present in Hy Reassortants.
Gene Ratio Gene Constellations Frequency
PB2 PB1 PA HA NP NA M NS
6:2 P P P WT P WT PP3 2
5:3 P WT P WT P WT PP1 3
PP P WT WT WT PP3
PP P WT P WT P WT 1
4:4 P WT P WT WT WT PP1
P WT P WT P WT WT P1
P WT P WT P WT P WT 1
3:5 WT WT WT WT P WT PP1
WT PP WT WT WT P WT 1
2:6 WT WT WT WT WT WT PP1
1:7 WT WT WT WT WT WT P WT 1
WT WT WT WT P WT WT WT 1
P: hy donor virus A/PR/8/1934 gene. WT: wild type virus gene.
doi:10.1371/journal.pone.0020823.t003
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Two reassortant families, NYMC X-163s and NYMC X-177s,
exhibited this characteristic. The difference in HA titer in the hy
reassortants generated from a common wt virus and hy donor with
the same 6:2 gene ratio is most likely due to point mutations in one
or more of the gene segments producing reassortants with different
growth characteristics in embryonated chicken eggs resulting in an
increase or decrease of HA titer.
The PB1 gene segment was the most frequent internal wt gene
segment present in our panel of hy reassortants (Figure 3). Our
analysis showed that in several hy reassortants from both the
H1N1 (e.g. NYMC X-179, X-181) and H3N2 (e.g. NYMC
X157A, X-165) subtypes the wt origin of the PB1 gene segment
produced a high growth phenotype. Enhanced growth of
reassortant virus containing wt PB1 was also seen for H5N2 avian
viruses. In the analysis by Rudneva et al. (2007) the reassortant BC-
R22-DP (5:3) produced from an H5N26PR8, the PB1 gene was of
wt virus origin; BC-R22-DP had higher viral titers as compared to
a 6:2 reassortant generated from the same wt virus. It has also
been shown that for 1918 H1N1 wt PB1, in a 1:7 gene
combination made with reverse genetics implementing A/
Texas/36/1991, was important for optimal replication, as well
as maximal virulence [29].
The reassortants produced from A/California/07/2009 for the
2009 H1N1pdm vaccine all had 5:3 gene ratios with PB1, HA and
NA genes coming from the wt virus. NYMC X-179, X-181 and X-
181A had the highest fold increase in this reassortant group. While
the fundamental characteristic of hy reassortants is the high
growth capacity in comparison to the respective wt virus, they
must be antigenically indistinguishable from the respective wt virus
in order to be considered a vaccine virus. NYMC X-179 is an
example of a vaccine candidate reassortant virus with high yield
that upon further analysis was found to have a mutation in the HA
resulting in altered antigenicity compared to wt; therefore it was
rejected as a vaccine virus [25]. Although the HA titer fold
increase was lower for NYMC X-179A in comparison with X-179,
it was antigenically indistinguishable from wt virus thereby
meeting the requirements to be used as a vaccine virus. In
contrast to NYMC X-179, NYMC X-181 and X-181A were
antigenically indistinguishable from wt [25]. An additional
example of selection for the wt PB1 gene segment in an H1N1
subtype was X-127 developed from A/Beijing/262/1995 and X-
31b. X-127 had a 4 fold increase in HA titer in comparison with
the respective wt virus.
Within the H3N2 subtype three reassortants, NYMC X-165
generated from A/Nepal/921/2006, NYMC X-167 generated
from A/Wisconsin/03/2007 and NYMC X-197 generated from
A/Brisbane/11/2010 had a 5:3 gene ratio that included the
respective wt PB1 gene segment and all three had a 16 fold HA
titer increase in comparison to wt. Interestingly, within a
reassortant family PB1 originating from wt confers the same hy
phenotype as PB1 originating from the hy donor PR8. Six
reassortants were produced from A/New York/55/2004, NYMC
X-157 to X157E. X-157A (5:3) obtained wt PB1 with the five
remaining internal genes from PR8 and has the same titer as X-
157 and X-157D, which have 6:2 gene ratios. In contrast in the
NYMC X-175 hy reassortant family this did not hold true. X-
175A had a 5:3 gene ratio, with PB1 originating from the wt virus
and a 4 fold increase in HA titer, while X-175C (6:2) had a 16 fold
increase, suggesting that in the X-175s, PB1 originating from PR8
may confer higher titers.
Our study suggests that for some reassortants, a complete
polymerase complex comprised of PB2, PB1 and PA from one
viral source may provide a growth advantage over a complete
polymerase complex from another viral source. The reassortants
NYMC X-147 and X-149 were both generated from the same wt
virus A/Wyoming/03/2003, but have the polymerase complex
composed of the three segments from two different donors, with
the remaining genetic background the same. X-147 (6:2) has the
complete polymerase complex from the hy donor PR8; X-149
(3:5) in contrast has the complete polymerase complex of wt virus
origin. The two hy reassortants had very different fold increases in
HA titer: X-147 had a 64 fold increase in HA titer whereas X-149
had a 16 fold increase in HA titer. Although X-149 retained all of
Figure 3. Frequency of Origin of Internal Genes in High Yield Reassortants.
doi:10.1371/journal.pone.0020823.g003
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presumably maintained the functional cooperation between the
three subunits, it did not confer the same growth characteristics
found when a complete polymerase complex was of PR8 origin. It
should be noted that the NP protein is a fundamental component
of the ribonucleoprotein complex thus the origin of the NP gene
segment may also influence the efficiency of the polymerase
complex. NYMC X-149 derived the NP gene from PR8, which
may not have interacted with the wt polymerase complex in the
most efficient manner in this reassortant.
Among the reassortants with a 5:3 gene ratio, the second most
common gene constellation had the NP gene segment derived
from the wt parent (Table 3). The NP gene segment was also the
second most common internal wt gene segment present among the
fifty-seven reassortants analyzed (Figure 3). Offringa et al. (2000)
analyzed five hy H3N2 reassortants, two of which, Resvir-9 and
X-125 had the same wt virus parent (A/Nanchang/933/1995).
The Resvir-9 and X-125 reassortants were produced in different
laboratories and both had 5:3 gene constellations, deriving the NP
gene from the wt virus. Our study also found reassortants that had
high HA titers while retaining the wt NP gene. Five reassortants
were produced for A/Brisbane/10/2007, NYMC X-171 to X-
171D. Among the five reassortants, two with the highest HA titers,
X-171C (5:3) and X-171D (5:3) had the NP gene segment
originating from wt virus; in contrast X-171B (6:2) had a 2 fold
lower HA titer. This suggests that the NP gene segment from wt
virus contributes to the hy trait for the X-171 reassortant group.
The wt virus NP gene segment may also be responsible for
contributing the hy phenotype to NYMC X-153 (5:3), which had
an 16 fold increase in HA titer over its’ wt parent.
Oxford et al. (1978) found the combination of the PR8 PB1 and
NP genes contributed hy characteristics to H3N2 reassortants,
although they could not determine the origin of the M gene. In our
analysis NYMC X-157E (1:7) acquired only the NP gene from
PR8 giving it a 2 fold increase in HA titer over the wt virus;
although within the X-157 family the reassortants that acquired
the majority of the genes from PR8 had the highest HA titers. In
contrast NYMC X-139 (4:4) an H1N1 reassortant derived the PB1
and NP gene segment from wt virus and had a 4 fold increase in
HA titer.
Of the fifty-seven reassortants analyzed, fifty-five reassortants
obtained the M gene from PR8 (Table 1). It is well documented in
the literature that the M gene segment from a hy donor is needed
in order to generate a hy reassortant [16–17,30]. This could be
attributable to the multiple functions of this protein. The M1
protein, located on the interior side of the viral envelope, is the
most abundant protein in the virion and affects virion morphol-
ogy. Filamentous viruses have a lower replicative titer in contrast
to the higher replication titers seen in viruses with spherical
morphology [5]. It has been shown that if a filamentous wt virus is
reassorted with PR8 resulting in progeny that have the M gene
segment derived from PR8, the reassortants will have spherical
morphology [31], perhaps granting a high growth phenotype to
the reassortants.
M1 also functions in the transport of the RNP complexes from
the nucleus to the cytoplasm. This is a critical step in viral particle
assembly. Liu et al. (2002) analyzed the binding affinity between
M1 and the RNP complex of Resvir-9 (A/Nanchang/933/
19956PR8, 5:3) in comparison to PR8 and to its’ respective wt
virus. Their study found that the binding affinity between the RNP
complex and M1 of Resvir-9 was similar to that of PR8; a lower
binding affinity between the RNP complex and M1 was found for
wt A/Nanchang/933/1995. Strong M1/RNP binding may
facilitate transport of the RNPs from the nucleus with resultant
viral particle assembly and maturation resulting in viral release
from infected cells [31]. NYMC X-161 (1:7), which had only the
M gene originating from PR8, had an 8 fold increase in HA titer
compared to wt. In another study Klimov et al. (1983) analyzed ten
hy reassortants that had acquired only the M gene segment from a
hy donor and found a strong correlation between the incorpora-
tion of the hy donor M gene segment and the hy phenotype.
It was determined that two reassortants in this analysis, NYMC
X-145 and NYMC X-157E, derived the M gene from wt rather
than from PR8. X-157E had six other wt gene segments in
addition to wt M and had the lowest titer in the X-157 family. The
second reassortant, X-145 in addition to the wt M gene also
obtained the PB1 gene from wt virus, with the remaining internal
genes derived from PR8. In this particular case although the M
gene originated from the wt virus, a hy reassortant was generated
with a 16 fold increase in HA titer. X-145 is the rare exception to
the well documented fact that hy reassortants normally obtain the
M gene segment from PR8.
The 6:2 gene ratio with only the HA and NA genes originating
from the wt virus is the most prevalent combination among hy
reassortants, but it is not the only gene ratio that results in high
titers. A fixed gene ratio may not be the best criterion for all
influenza vaccine candidates. Rudneva et al. (2007) has shown
that H5 reassortants with a 5:3 gene ratio grow to higher titers
than H5 reassortants that are 6:2. In our study, 5:3 gene ratios
also conferred titers as high as 6:2 gene ratios, and in certain
reassortants even higher titers. We also found a single 2:6 gene
ratio and multiple unique gene constellations (Table 3). The
optimal gene combinations may facilitate replication through
viral RNA and protein interaction with cellular components as
well as interaction of viral RNA and protein or protein-protein
interactions within the virus. These multi-factorial contributions
result in selection of a high replication competent reassortant in
embryonated chicken eggs in comparison to the respective low
yield wt viruses. Preparation of hy reassortants by classical
reassortment allows selection of reassortant viruses in ovo with the
optimal gene ratio and gene constellation that grant the highest
growth. This study demonstrates that the gene ratio and gene
constellation yielding a reassortant with hy phenotype is




Viruses designated with an X, i.e. X-53 through X-145, have
been obtained from the laboratory of Dr. Edwin D. Kilbourne.
Viruses designated NYMC X, i.e. NYMC X-147 through NYMC
X-197, are from the laboratory of Dr. Doris Bucher. The viral
panel used for this study was composed of fifty-seven hy
reassortants and their respective wt and hy donor viruses
(Table 1). Reassortants were generated according to established
methods [4–5]. Hy donor virus and a wt virus were co-inoculated
in ovo. After 42–48 hour incubation at 35uC the allantoic fluid was
harvested. The mixed reassortant progeny were subjected to
negative selection by the addition of antiserum or purified
antibodies prepared from sera of rabbits (PRF&L Inc., Canaden-
sis, PA) immunized with hy donor virus or hy donor virus surface
glycoproteins; this was followed by in ovo incubation for 42–
48 hour at 35uC. The negative selection step was repeated two
additional times. The resultant reassortant viruses were harvested
and amplified by further incubation cycles without antisera/
antibodies. The allantoic fluids were harvested and the reassortant
viruses cloned by limiting dilution.
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Relative viral titers were determined using a standard
hemagglutination assay (HA). 50 ml PBS was added to each well
of a V-shaped 96-well microtiter plate. 50 ml of harvested allantoic
fluid was added to the first well in column one, serial dilutions
were made by transferring 50 ml from the first well of column one
to the successive columns, the final 50 ml were discarded. 50 mlo f
0.5% chicken red blood cell suspension (PRF&L Inc., Canadensis,
PA) was added to each well on the plate. Using a microtiter plate
shaker, the contents of the plate were agitated and incubated at
room temperature for 30 minutes [32].
RNA Preparation
RNA was isolated from 280 ml of allantoic fluid using QIAmpH
Viral RNA Mini Kit (Qiagen Inc., Valencia, CA) per manufac-
turer’s recommendations. The RNA samples were stored at
220uC until further use.
Reverse transcription and PCR amplification
Primers were designed in order to include the 39 and 59
conserved regions in addition to 8–11 extra nucleotides that were
segment specific. Primers were synthesized by Integrated DNA
Technologies Inc. (Coralville, IA). Forward (F) and reverse (R)
primers used for PCR amplification of gene segments are shown in
Table 4. RT-PCR was performed using Takara One Step RNA
PCR Kit (Takara Bio Inc., Otsu, Shiga, Japan) per manufacturer’s
recommendations. Briefly 2 mg of vRNA was added to the
following mixture: 106 One Step RNA PCR Buffer, 5mM
MgCl2, 1mM dNTP, 0.8U/ml RNase Inhibitor, 0.1U/ml AMV
RTase XL, 0.1U/ml AMV-Optimized Taq, 0.4 mM each of
forward and reverse primers, and RNase free H2O up to a total
volume of 50 ml. RT-PCR parameters used were as follows: 55uC
for 30 minutes, 94uC for 2 minutes, followed by 35 cycles of 94uC
for 30 seconds, 55uC for 1 minute (HA, NP, NA, M and NS gene
segments) or 61uC for 1 minute (PB2, PB1 and PA gene segments),
68uC for 2 minutes and a final extension at 72uC for 10 minutes.
The reactions were performed on an Eppendorf MastercyclerH
(Eppendorf AG, Hamburg, Germany). The amplified RT-PCR
products were visualized on a 2% agarose-TAE/EtBr gel.
DNA purification
PCR products were gel purified in a 2% low melt agarose gel
using QIAquickH Gel Extraction Kit (Qiagen Inc., Valencia, CA)
per manufacturer’s recommendations. The extracted PCR
products were visualized for purity on a 2% agarose-TAE/EtBr
gel.
Restriction Fragment Length Polymorphism (RFLP)
Analysis
Gene segment sequences were analyzed using RestrictionMapper
(http://www.restrictionmapper.org/) in order to identify restric-
tion enzymes that recognized the least number of cut sites per gene
segment. Purified segment specific DNA was digested with the
respective restriction enzymes (Table 2). The digestion reactions
were in 10 ml volume with 10 units of the designated enzyme and
incubated for 3 hrs following reaction conditions recommended by
the manufacturers (NEB, Ipswich, MA or Fermentas Inc., Glen
Burnie, MD). The DNA from the hy donor virus, wt virus and
their respective reassortants was digested concurrently. The
digestion reactions were visualized on a 2% agarose-TAE/EtBr
gel.
Statistical analysis
Statistical significance of gene constellation frequency was
analyzed using a chi-square test. Number Cruncher Statistical
System (NCSS, Kaysville, UT) was used for the analysis. A value
of p,0.05 was considered statistically significant.
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